Pneumocystis jirovecii pneumonia in anti-MDA5-positive dermatomyositis: characterisation, risk factors and prognosis
PJP significantly increases early mortality of anti-MDA5+DM patients. Clinicians should identify high-risk patients early and administer prophylactic-dose TMP/SMZ for PJP prophylaxis.
Authors
- Qihua Yang (ORCID: https://orcid.org/0000-0001-7183-3366)
- Jing Li (ORCID: https://orcid.org/0009-0007-3236-9637)
- Lijuan Zhang (ORCID: https://orcid.org/0000-0003-3216-3608)
- Shengyun Liu (ORCID: https://orcid.org/0000-0003-3197-3158)
- Chaofeng Lian
- Lu Yang (ORCID: https://orcid.org/0009-0009-6562-7748)
Institutions
- First Affiliated Hospital of Zhengzhou University (CN)
Publication Details
- Journal
- Clinical and Experimental Rheumatology
- Published
- 2025-02-10
- DOI
- https://doi.org/10.55563/clinexprheumatol/hpx173
- Primary Topic
- Pneumocystis jirovecii pneumonia detection and treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00